AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9640069
Drug: Pelentan (Hypoprothrombinemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelentan (Hypoprothrombinemia Provocation Test) administered to patients with suspected hepatic injury and alcohol abusers
Trial: 9640069
Drug: Pelentan (Hypoprothrombinemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelentan (Hypoprothrombinemia Provocation Test) administered
Trial: 9640069
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (clinically healthy people not exposed to toxic agents)
Trial: 31493725
Drug: tDCS applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tDCS applied during MT (concurrent‐tDCS group)
Trial: 18387567
Drug: Finger-differentiation training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finger-differentiation training programme (G1) - 2 weekly sessions of half an hour each for 8 weeks
Trial: 10027429
Drug: Zafirlukast (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast (20 mg twice daily) with PEF variability >= 20%
Trial: 10027429
Drug: Zafirlukast (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast (20 mg twice daily) with PEF variability < 20%
Trial: 2405348
Drug: aluminum ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aluminum ibuprofen suspension for 2 weeks
Trial: 2405348
Drug: control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (no treatment)
Trial: 7008643
Drug: Domperidone 10
RxNorm normalized name: domperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg I.V.
Trial: 22986242
Drug: Topical antifungal
RxNorm normalized name: Imidazole and triazole derivatives, topical antifungals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antifungal therapy (nystatin, 1 or 3 times/week for 14 days)
Trial: 20350598
Drug: Transdermal patches
RxNorm normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patches with polyacrylate pressure sensitive adhesives
Trial: 18671241
Drug: Amifostine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (500 mg subcutaneously 3 times weekly)
Trial: 18671241
Drug: Epoetin-alpha (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-alpha (10,000 IU subcutaneously 3 times weekly)
Trial: 15562376
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg/d for 24 weeks)
Trial: 7532192
Drug: L-selectin expression
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-selectin expression
Trial: 1646613
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of apafant (20 mg to 400 mg)
Trial: 1646613
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of apafant (100 mg t.i.d. over 7 days)
Trial: 1646613
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of apafant (0.5 to 50 mg over 30 min)
Trial: 1646613
Drug: Inhalative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalative administration of apafant (up to 1.0 mg)
Trial: 1646613
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of apafant (capsules)
Trial: 7148760
Drug: Both enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both enzyme preparations
Trial: 29669748
Drug: 0 mg/mL
RxNorm normalized name: urea 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/mL e-liquid
Trial: 29669748
Drug: 6 mg/mL
RxNorm normalized name: phenol 6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/mL e-liquid
Trial: 29669748
Drug: 12 mg/mL
RxNorm normalized name: niacin 12 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/mL e-liquid
Trial: 29669748
Drug: 24 mg/mL
RxNorm normalized name: sulfur 24 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg/mL e-liquid
Trial: 27922279
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (cetrorelix) at low dose
Trial: 19234342
Drug: Sub-Tenon's injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-Tenon's injection of 25 mg triamcinolone and 2 mg ciprofloxacin in biodegradable microspheres
Trial: 17768459
Drug: Standard plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard plus relaxation therapy, 2 times per week, for 8 weeks
Trial: 12439918
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy after gastrectomy
Trial: 7577778
Drug: 0.05% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% bupivacaine at 10 mL/h
Trial: 7577778
Drug: 0.1% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bupivacaine at 10 mL/h
Trial: 7577778
Drug: 0.01% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% bupivacaine at 10 mL/h
Trial: 7577778
Drug: 1 mg/h
RxNorm normalized name: fentanyl 0.1 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/h bupivacaine
Trial: 83475
Drug: Inactivated influenza-A
RxNorm normalized name: influenza A virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza-A vaccine
Trial: 83475
Drug: Annual revaccination
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual revaccination with inactivated influenza-A vaccine
Trial: 23789838
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with Sebium H2O Micellaire Solution (Control)
Trial: 21407074
Drug: tCSA once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tCSA once daily (n = 50)
Trial: 21407074
Drug: tCSA twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tCSA twice daily (n = 50)
Trial: 17369597
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) for chronic fatigue syndrome
Trial: 11473555
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas inflow of 1.0 L min-1
Trial: 11473555
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas inflow of 2.0 L min-1
Trial: 9724561
Drug: Ranitidine 75
RxNorm normalized name: ranitidine 75 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 75 mg b.i.d. for 8 days
Trial: 9724561
Drug: Racemic chlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic chlorpheniramine 4 mg single oral dose
Trial: 8056698
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg i.v. tds
Trial: 8056698
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg po bd
Trial: 2451231
Drug: Porous titanium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porous titanium steroid eluting electrode with dexamethasone sodium phosphate
Trial: 2451231
Drug: Porous titanium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porous titanium electrode without steroid
Trial: 12587122
Drug: Talinolol (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talinolol (four marketed tablet formulations)
Trial: 10678268
Drug: no-drug control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no-drug control state
Trial: 3539163
Drug: Epoprostenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoprostenol infusion (5 ng/kg/min, mean dose 4.9 ng/kg/min, 72 hour infusion)
Trial: 26242047
Drug: Shugan Jieyu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shugan Jieyu Capsules (SJC)
Trial: 20936994
Drug: Inhaled montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled montelukast 100 μg
Trial: 20936994
Drug: Inhaled montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled montelukast 250 μg
Trial: 20936994
Drug: Inhaled montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled montelukast 1000 μg
Trial: 20936994
Drug: Montelukast (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (pooled doses) plus albuterol
Trial: 12930168
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.35 g.kg(‐1).d(‐1) for 7 days)
Trial: 12412676
Drug: Terbutaline 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 0.5 mg
Trial: 27354202
Drug: Amitriptyline (tricyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (tricyclic antidepressant)
Trial: 6438686
Drug: Clovoxamine (nontricyclic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clovoxamine (nontricyclic, experimental antidepressant)
Trial: 31071760
Drug: 1% sodium
RxNorm normalized name: Dextrose 5% and 0.11% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% sodium alendronate gel
Trial: 25097010
Drug: Antiangiogenic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiangiogenic drugs
Trial: 19382637
Drug: Diaskintest (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaskintest (0.2 microg in 0.1 ml)
Trial: 19382637
Drug: Tuberculin skin
RxNorm normalized name: tuberculin skin test; unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuberculin skin test (Mantoux test with 2 TE of PPD L-2)
Trial: 17545533
Drug: Elacridar 100
RxNorm normalized name: Elacridar
DrugBank: Elacridar (DB04881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elacridar 100 mg coadministered with oral topotecan 2.0 mg
Trial: 17545533
Drug: Oral topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan 2.5 mg
Trial: 17545533
Drug: Recommended schedule:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended schedule: 2.0 mg oral topotecan plus 100 mg elacridar
Trial: 15837645
Drug: Irrigating solution
RxNorm normalized name: IRRIGATING SOLUTIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigating solution of Sihuang (ISSH)
Trial: 16960944
Drug: Topical nonsteroidal
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nonsteroidal antiinflammatory drugs (NSAIDs)
Trial: 10321415
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (150 or 300 mg/d)
Trial: 10321415
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (100, 200, 300, or 400 mg/d)
Trial: 10321415
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (50 to 150 or 100 to 300 mg/d)
Trial: 8562960
Drug: G‐CSF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (300 micrograms subcutaneously)
Trial: 1992393
Drug: Nifedipine (10‐30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10‐30 mg sublingually, then 40‐120 mg/day orally)
Trial: 1992393
Drug: Hydralazine (6.25‐12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (6.25‐12.5 mg intravenously, then 80‐120 mg/day orally)
Trial: 31444617
Drug: Fedratinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fedratinib (200 mg and above)
Trial: 30024999
Drug: 0.2% chlorhexidine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine-based solution (positive control)
Trial: 24750904
Drug: Ceftriaxone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone at a dose of 2 g, given every 24 hours intravenously for four days, in addition to stroke-unit care
Trial: 21700408
Drug: RFA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RFA treatment
Trial: 17346705
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin applied at and just above the level of spinal cord injury
Trial: 16259624
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (supervised sessions three times per week for eight weeks)
Trial: 12177109
Drug: GSH (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSH (1,500 mg/m(2) over a 15-minute infusion before oxaliplatin)
Trial: 7760093
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg methohexital
Trial: 7760093
Drug: 2 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 micrograms/kg fentanyl and 0.15 mg/kg midazolam
Trial: 7760093
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg ketamine and 0.15 mg/kg midazolam
Trial: 23380426
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg twice daily for 9 days
Trial: 23380426
Drug: Tolbutamide 500
RxNorm normalized name: tolbutamide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide 500 mg single dose on Day 5
Trial: 1672569
Drug: Luteinising-hormone releasing-hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinising-hormone releasing-hormone (LH-RH), 1.2 mg daily intranasally for four weeks
Trial: 6555015
Drug: Cefonicid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid (1 g intramuscularly)
Trial: 6555015
Drug: Amoxicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (500 mg orally three times a day for 7 days)
Trial: 30703077
Drug: Recombinant zoster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant zoster vaccine (RZV; Shingrix)
Trial: 26563608
Drug: Ropivacaine continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine continuous infusion (group R)
Trial: 26563608
Drug: Saline continuous
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline continuous infusion (placebo, group P)
Trial: 24831421
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication (gabapentin or pregabalin)
Trial: 21898137
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 20 mg/kg IV over 15 min
Trial: 21898137
Drug: Lorazepam (LOR)
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorazepam (LOR) 0.1 mg/kg IV over 2-4 min
Trial: 19713172
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d seaweed (Undaria pinnatifida)
Trial: 19713172
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d seaweed
Trial: 19713172
Drug: 6 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/d seaweed
Trial: 18549664
Drug: Doripenem 500
RxNorm normalized name: doripenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doripenem 500 mg every 8 h by a 1-h intravenous infusion
Trial: 18549664
Drug: Piperacillin/tazobactam 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 4.5 g every 6 h by 30-min IV infusion
Trial: 16148021
Drug: Dose-dense sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense sequential chemotherapy with epirubicin (110 mg/m2) followed by paclitaxel (250 mg/m2) and intensified CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2, fluorouracil 840 mg/m2)
Trial: 16148021
Drug: Dose-dense sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense sequential chemotherapy with epirubicin followed by paclitaxel and intensified CMF
Trial: 8850378
Drug: L-propionylcarnitine 500
RxNorm normalized name: arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-propionylcarnitine 500 mg tid for 6 weeks
Trial: 2211201
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (consolidation radiotherapy after induction chemotherapy)
Trial: 374163
Drug: Two 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 225 mg tablets of Phyllocontin (slow-release aminophylline)
Trial: 27052634
Drug: Metformin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1.5 g/day)
Trial: 18056903
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus GP IIb/IIIa inhibitors (n = 4603)
Trial: 18056903
Drug: Bivalirudin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin plus GP IIb/IIIa inhibitors (n = 4604)
Trial: 18056903
Drug: Bivalirudin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin monotherapy (n = 4612)
Trial: 18056903
Drug: Deferred use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred use of GP IIb/IIIa inhibitors
Trial: 7744539
Drug: Moricizine HCl
RxNorm normalized name: moricizine HCl
DrugBank: Moricizine (DB00680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine HCl at 200 mg twice daily for 5 days
Trial: 6216612
Drug: Aqueous procaine
RxNorm normalized name: Aqueous procaine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous procaine penicillin G (4.8 x 10(6) units plus 1 g of oral probenecid)
Trial: 6216612
Drug: Spectinomycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin (2 g)
Trial: 31990877
Drug: SMS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS group (received SMS about bowel preparation practices 3 days before colonoscopy)
Trial: 18640632
Drug: Aromatherapy treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy treatment, details on dosage and duration not specified.
Trial: 12816787
Drug: Commercial milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial milk-based cereal drink (MCD) and porridge (CC group)
Trial: 6141926
Drug: 1% pindolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% pindolol eye-drops, twice daily
Trial: 6141926
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol eye-drops, twice daily
Trial: 30768462
Drug: Early rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early rocuronium administration (n = 58)
Trial: 30768462
Drug: Late rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late rocuronium administration (n = 56)
Trial: 24119983
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hemostatic treatment)
Trial: 10446691
Drug: Troglitazone 200
RxNorm normalized name: troglitazone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 200 mg twice daily (group A)
Trial: 7768546
Drug: Oral typhoid
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral typhoid vaccine (Ty21a)
Trial: 911030
Drug: BCG adjuvant
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG adjuvant immunotherapy
Trial: 23855973
Drug: 5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/d of fish oil (providing 3 g of EPA + DHA)
Trial: 10743982
Drug: Intact lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intact lansoprazole capsule (regimen D)
Trial: 10376262
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg midazolam
Trial: 8922766
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg midazolam plus 250 micrograms alfentanil
Trial: 1388952
Drug: Mechanical oral
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical oral hygiene (wooden interdental cleaner)
Trial: 27433812
Drug: Gatorade and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatorade and 357 g of PEG (day-prior dose)
Trial: 27433812
Drug: Split-dose bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split-dose bowel preparations (3 different types)
Trial: 27433812
Drug: Split-dose bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split-dose bowel preparations
Trial: 17223409
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of simvastatin
Trial: 16999946
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of simvastatin
Trial: 11368263
Drug: Clindamycin vaginal
RxNorm normalized name: clindamycin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin vaginal ovules (3-day treatment)
Trial: 11368263
Drug: Clindamycin vaginal
RxNorm normalized name: clindamycin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin vaginal cream (7-day treatment)